Significant time savings with prehospital administration of Retavase in ER-TIMI 19 trial* |
|
|
 |
 |
Prehospital administration saved a median of 32 minutes (p<0.0001) from the time of first medical contact to initiation of Retavase |
|
|
|
In-hospital adverse events observed with prehospital administration of Retavase |
|
|
|
Cardiogenic shock, 7.3%; death, 4.7%; reinfarction, 3.3%; major hemorrhage, 1.7%; intracranial hemorrhage, 1%; and nonhemorrhagic stroke, 1% |
|
|
Significantly higher percentage of patients treated within 30 minutes of medical contact |
|
|
|
|
|
By 30 minutes after medical contact, 49% of prehospital patients had started treatment, compared with 5% of in-hospital patients |
|
|
|
By 60 minutes after medical contact, 97% of prehospital patients had started treatment, compared with 48% of in-hospital patients |
|
|
|
Prehospital administration of Retavase resulted in a 10-fold increase of patients treated within 30 minutes |
|
|
|
*Early Retavase-Thrombolysis in Myocardial Infarction (ER-TIMI) 19 trial, a multicenter study comparing door-to-drug times in patients receiving prehospital Retavase (enrolled, n=315; evaluable, n=313) with sequential control patients (n=630) who received a fibrinolytic in the hospital. |
|
Important Safety Information |
|
Because thrombolytic therapy increases the risk of bleeding, including internal bleeding (such as intracranial, retroperitoneal, gastrointestinal, genitourinary, or respiratory), Retavase should be used only in those patients for whom its use is indicated in the prescribing information
(see "Indications" in the prescribing information). In addition, thrombolytic therapy increases the absolute risk of stroke, including hemorrhagic stroke, in patients of advanced age. Cholesterol embolism has been reported rarely in patients treated with thrombolytic agents. Coronary thrombolysis may result in arrhythmias associated with reperfusion (see "Warnings" in the prescribing information). |
|
|
|
|
